2023-09-25 09:16:59 ET
(24/7 MARKET NEWS) – TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced this morning today that its lead therapeutic candidate, TTX-MC138, was delivered to brain tumors and effectively engaged its target in murine models bearing human glioblastoma multiforme (GBM) tumors, the most common and aggressive form of brain cancer.
TransCode Therapeutics is trading at $0.81, up $0.146 (+ 21.68%), on 2.47M premarket shares traded.
Its 52-week range is $0.4998 to $31.00. If it can hold today’s gains it may be able to reverse its long-term downward trend.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is …
The post TransCode Therapeutics’ Lead Therapeutic Candidate, TTX-MC138, effectively engaged its Target appeared first on 24/7 Market News .
For further details see:
TransCode Therapeutics’ Lead Therapeutic Candidate, TTX-MC138, effectively engaged its Target